Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study aims to evaluate the efficacy and safety of combining low-dose oral minoxidil with spironolactone for treating female androgenetic alopecia, amid concerns about potential blood pressure effects, though the results are not reported here.

This study reported that topical spironolactone improved lid margin vascularity, corneal fluorescein staining, and disease severity scores in patients with ocular graft-versus-host disease, suggesting a potential therapeutic role by enhancing corneal lipid production with minimal adverse effects.

This study found that combining topical minoxidil with microneedling improved hair density more than either minoxidil alone or with spironolactone for women with mild-to-moderate female pattern hair loss.

This study found that spironolactone may improve acne and some ovarian functions in patients with irregular menstrual periods and androgenic symptoms, while causing few side effects.

This case report describes two women experiencing hormonally associated vestibulodynia and female arousal disorder, potentially linked to the use of spironolactone for androgen-mediated cutaneous disorders.

Leuprolide may better manage cholesterol and blood pressure in PCOS than spironolactone.

This study found that systemic ovalbumin–aluminum sensitization followed by cutaneous challenge in mice induced thermal hyperalgesia, increased spinal cord gliosis, and sprouting of nociceptive fibers, along with elevated mast cell and nerve profile densities in the skin compared to controls.

In this study, a pregnant woman inadvertently exposed to spironolactone delivered a healthy male infant with normal genitalia, highlighting the need for more research on the safety of spironolactone and new-generation mineralocorticoid receptor antagonists during pregnancy.

This study found that spironolactone improved cognitive performance in patients with bipolar disorder experiencing manic episodes, but did not significantly affect manic symptoms, recommending further research with larger sample sizes and longer follow-ups.

In a retrospective study, researchers found that topical spironolactone improved tear film quality and reduced inflammation related to meibomian gland dysfunction and evaporative dry eye in patients, demonstrating good tolerability and suggesting it as a potential therapy for managing the condition.

This study found that combining 5% topical minoxidil and 5% topical spironolactone solutions may enhance treatment efficacy for androgenetic alopecia in both men and women, with significant reductions in vellus hair.

This study found that Spironolactone-loaded ethosomal gels provided superior skin permeation and deposition compared to niosomal gels in rabbit skin, suggesting that ethosomal gels could be a promising formulation for further clinical studies on treating androgenic alopecia.

This study found that oral spironolactone is generally well tolerated and may be effective for treating female-pattern hair loss, with improvements in hair regrowth stability as measured by Sinclair scores.

This article discusses the underutilization of spironolactone in dermatology for conditions like acne, highlighting its potential benefits and good safety profile, but reports no new clinical findings.

Spironolactone and finasteride are equally effective for hirsutism in transgender women.

This case report highlights a rare adverse event where a patient with inactive idiopathic papilledema experienced increased intracranial pressure after taking spironolactone, which resolved upon discontinuation of the drug.

This study found that supplementation with Aloe vera and Spirulina fusiformis effectively improved the appearance of rabbit skin tissue, particularly in hair texture and skin attributes.

This study suggests that long-term treatment with valproate, acetylcarnitine, folic acid, and vitamin B12 may benefit children with SMA types II and III by improving muscle strength and function without significant adverse effects.

This article discusses hyperandrogenism syndrome in women, highlighting systemic antiandrogenic therapy as advisable for severe or moderate hirsutism but reports no new clinical results.

This study found that despite a high incidence of side effects, patients generally tolerated spironolactone while benefiting from its treatment effects for acne and hirsutism.

This study concluded that the liquid chromatography-mass spectrometry method developed is viable for accurately quantifying spironolactone and its metabolite canrenone in plasma despite interference from plasma components.

This paper reviews the current evidence regarding the off-label use of spironolactone for acne management, noting that despite its long-standing application in acne treatment, it has not yet received FDA approval for this indication.

This retrospective cohort study found that both spironolactone and bicalutamide significantly improved Sinclair grade in women with female pattern hair loss over 24 months, but spironolactone, especially at doses above 100 mg/day, resulted in greater efficacy, required less monitoring, and maintained comparable safety.

In this case report, a 67-year-old woman with Netherton syndrome experienced significant improvement in skin inflammation, pruritus, and hair growth after treatment with dupilumab, suggesting potential benefits for addressing both cutaneous and hair manifestations of the condition.

This case study documented that a 67-year-old woman with Netherton syndrome experienced significant improvements in skin inflammation, pruritus, and hair growth after treatment with dupilumab, addressing symptoms of the syndrome and showing promising results for resolving "bamboo" hair.

Nanocarriers with spironolactone and 2-deoxy-D-ribose may improve hair loss treatment by targeting hair follicles directly.

In this study, researchers discovered a honeycomb-like structure in the skin of spiny mice that facilitates tissue shedding and regeneration, attributed to a uniquely arranged collagen VI and influenced by spiny hair development.

In this randomized trial, bicalutamide was found to improve hair count and shaft diameter more than spironolactone in women with Female Pattern Hair Loss over 24 weeks, although no significant differences were observed in clinical endpoints between the two treatments.

This study reports that spironolactone, a potassium-sparing diuretic with antiandrogenic activity, effectively improves hair density, reduces shedding, and stabilizes symptoms in female pattern hair loss, though symptoms often recur after discontinuation, suggesting the need for sustained therapy.